कंपनी का अवलोकन
Valneva SE operates as a specialty vaccine company dedicated to the development, manufacturing, and commercialization of prophylactic vaccines designed to address infectious diseases with unmet medical needs. The firm primarily offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis, positioning it within the broader healthcare sector. Specifically, the company functions within the biotechnology industry, focusing on the specialized segment of vaccine research and production rather than general pharmaceuticals. In terms of scale, Valneva SE holds a market capitalization of $561.35M and reported an annual revenue of $174.66M, while employing a workforce of 674 individuals. These valuation and revenue figures indicate that the company maintains a mid-cap profile with a significant revenue stream relative to its employee base, suggesting a specialized operational model where high-value intellectual property drives income generation rather than mass-market volume sales typical of larger pharmaceutical entities.
वित्तीय स्वास्थ्य
The company reported a revenue of $174.66M for the trailing twelve months, yet recorded a net income of $-115,192,000 and an EBITDA of $-64,702,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and research costs significantly exceed gross margins, resulting in a net loss despite commercial sales activities. Furthermore, the free cash flow stands at $-49,673,376, which indicates that the company is currently burning cash to fund its operations and development pipeline, thereby limiting its immediate financial flexibility for large-scale capital expenditures without external financing. Analyzing the profitability metrics, the gross margin is reported at -10.2%, reflecting that production costs currently exceed the revenue generated from vaccine sales. The operating margin sits at -58.1%, while the profit margin is -66.0%, both figures highlighting severe operational inefficiencies or high research and development expenditures relative to current sales volumes. Regarding liquidity and leverage, the company holds cash reserves of $109.65M against total debt obligations of $207.25M, resulting in a debt-to-equity ratio of 195.21, which characterizes the balance sheet as highly leveraged. The current ratio of 2.38 suggests that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises despite the long-term debt burden. Return on Equity is recorded at -80.2% and return on assets at -11.4%, metrics that reveal management is currently unable to generate positive returns on shareholder capital or total assets, indicating a phase of heavy investment or operational challenge rather than profitability.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A due to the net loss, while the forward P/E stands at 7.72, implying that the market expects a trajectory toward profitability that could significantly alter the valuation multiple in future periods. The price-to-book ratio is 8.82, indicating that the market values the company's equity at a substantial premium over its book value, likely reflecting the high intangible value of its vaccine patents and intellectual property rather than physical assets. Alternative valuation metrics such as the price-to-sales ratio of 3.21 and an EV/EBITDA of -18.26 suggest that investors are pricing the stock based on future revenue potential and growth prospects rather than current earnings power or cash flow generation. The stock has traded within a 52-week range with a high of $12.25 and a low of $5.43, and without a specific current price listed in the provided facts, the valuation context must be understood relative to this established volatility band where the asset has demonstrated significant price movement. The beta value of 1.53 indicates that the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the average market index during periods of equity market fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at -9.9%, while earnings growth is N/A due to the absence of positive net income in the prior period. The decline in revenue suggests a contraction in sales volume or pricing pressure, and since earnings are negative, the concept of earnings growing faster or slower than revenue is currently moot until profitability is restored. As a non-dividend payer, Valneva SE reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company does not distribute income to shareholders but instead retains all available cash to reinvest into its vaccine development programs and operational infrastructure. This strategy of reinvestment rather than dividend distribution is typical for biotechnology firms in growth or development phases that prioritize capital allocation toward R&D and commercialization over immediate shareholder returns. Overall, the growth and income profile of Valneva SE is currently characterized by revenue contraction and a lack of income generation, reflecting a capital-intensive business model where returns are expected to materialize only after the current negative earnings phase concludes and the vaccine portfolio achieves broader commercial success.